Want to see NVCT full AI Analyst Report?
Total Valuation
Nuvectis Pharma has a market cap or net worth of $689.44M. The enterprise value is $409.56M.
Market Cap$689.44M
Enterprise Value$409.56M
Share Statistics
Nuvectis Pharma has 32,644,066 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,644,066
Owned by Insiders34.86%
Owned by Institutions18.14%
Financial Efficiency
Nuvectis Pharma’s return on equity (ROE) is -1.44 and return on invested capital (ROIC) is -149.75%.
Return on Equity (ROE)-1.44
Return on Assets (ROA)-0.83
Return on Invested Capital (ROIC)-149.75%
Return on Capital Employed (ROCE)-1.50
Revenue Per Employee0.00
Profits Per Employee-1.65M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nuvectis Pharma is ―. Nuvectis Pharma’s PEG ratio is -0.30.
PE Ratio―
PS Ratio0.00
PB Ratio8.94
Price to FCF-10.29
Price to Operating Cash Flow-25.41
PEG Ratio-0.30
Income Statement
In the last 12 months, Nuvectis Pharma had revenue of 0.00 and earned -26.44M in profits. Earnings per share was -1.32.
Revenue0.00
Gross Profit0.00
Operating Income-27.57M
Pretax Income-26.44M
Net Income-26.44M
EBITDA-26.44M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -19.51M and capital expenditures 0.00, giving a free cash flow of -19.51M billion.
Operating Cash Flow-19.51M
Free Cash Flow-19.51M
Free Cash Flow per Share-0.60
Dividends & Yields
Nuvectis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change241.20%
50-Day Moving Average21.77
200-Day Moving Average13.79
Relative Strength Index (RSI)48.46
Average Volume (3m)190.40K
Important Dates
Nuvectis Pharma upcoming earnings date is Nov 10, 2026, Before Open (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
Nuvectis Pharma as a current ratio of 2.38, with Debt / Equity ratio of 0.00%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.00
Net Debt to EBITDA1.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nuvectis Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nuvectis Pharma EV to EBITDA ratio is -5.03, with an EV/FCF ratio of -8.31.
EV to Sales0.00
EV to EBITDA-5.03
EV to Free Cash Flow-8.31
EV to Operating Cash Flow-8.31
Balance Sheet
Nuvectis Pharma has $22.16M in cash and marketable securities with $0.00 in debt, giving a net cash position of $22.16M billion.
Cash & Marketable Securities$22.16M
Total Debt$0.00
Net Cash$22.16M
Net Cash Per Share$0.68
Tangible Book Value Per Share$0.84
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nuvectis Pharma is $34.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.33
Price Target Upside44.68% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-13.52%